Research programme: cancer therapeutics - Qurgen
Latest Information Update: 29 Sep 2023
At a glance
- Originator Qurgen
- Class Antineoplastics; Immunotherapies; Proteins
- Mechanism of Action Cell differentiation modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 27 Aug 2023 Qurgen has patent protection and patents pending, regarding "Methods, systems and compositions relating to cell conversion via protein induced in-vivo cell reprogramming" in various countries
- 24 Aug 2023 Preclinical trials in Solid tumours in China (unspecified route) (Qurgen pipeline, August 2023)
- 24 Aug 2023 Preclinical trials in Solid tumours in USA (unspecified route) (Qurgen pipeline, August 2023)